Almotriptan, a new anti-migraine agent: A review

CNS Drug Reviews

Volumn 8, Issue 3, 2002, Pages 217-234

  Gras, Jordi ^a   Llenas, Jesús ^a   Jansat, Josep M ^a   Jáuregui, José ^a   Cabarrocas, Xavier ^a   Palacios, José M ^a  

^a Research Center ^*  (Spain)

Author keywords

5 HT1B 1D receptors; Almotriptan; Migraine; Triptans

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; CYTOCHROME P450; FLUOXETINE; PROPRANOLOL; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN 7 RECEPTOR; SUMATRIPTAN; UNSPECIFIC MONOOXYGENASE; VERAPAMIL;

ANXIETY NEUROSIS; AREA UNDER THE CURVE; BINDING AFFINITY; CLINICAL TRIAL; DEPRESSION; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; HEADACHE; HUMAN; KIDNEY FAILURE; MOUSE; MYALGIA; NAUSEA; NONHUMAN; PARESTHESIA; RAT; REVIEW; SALIVARY GLAND DISEASE; SOMNOLENCE; THORAX PAIN; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0036749926     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2002.tb00226.x     Document Type: Review

References (45)

1. Bou J, Domènech T, Puig J, et al. Pharmacological characterization of almotriptan: An indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 2000;410:33-41.
2. Bou J, Gras J, Cortijo J, Morcillo E, Llenas J, Palacios J. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 2001;21:804-812.
3. Cabarrocas X, Salvà M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. 8th Congress of the International Headache Society, Amsterdam, 10-14 June 1997.
4. Coote JH, Dalton DW, Feniuk W, Humphrey PPA. The central site of the sympatho-inhibitory action of 5-hydroxytryptamine in the cat. Neuropharmacology 1987;26:147-154.
5. l-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol 1991;102:323-330.
6. Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH. Disposition of sumatriptan in laboratory animals and humans. Drug Metab Dispos 1993;21:761-769.
7. Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 2001;41:449-455.
8. Engel J, Scheffler G, Nickel B, et al. Anpirtoline Hydrochloride. Drugs Future 1989;14:614.
9. Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR 43175 in anaesthetized dogs. Br J Pharmacol 1989;96:83-90.
10. Fernandez FJ, Jansat JM, Cabarrocas X, Costa J, Salva P. Absolute bioavailability of oral and subcutaneous almotriptan. Cephalalgia 1999;19:363 (Abstr.).
11. Ferrari MD. Migraine. Lancet 1998;351:1043-1051.
12. 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001;358:1668-1675
13. 1 receptors in migraine pathophysiology and treatment. Eur J Neurol 1995;2:5-21.
14. Fleishaker JC, Ryan KK, Carel BJ, Azie NE. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol 2001;41:217-223.
15. Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol 2001;51:437-441.
16. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000;67:498-503.
17. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia 2001;21:61-65.
18. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000;62:509-525.
19. Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: A randomised controlled trial. Lancet 2001;358:1230-1234.
20. Gomez-Mancilla B, Cutler NR, Leibowitz MT, et al. Safety and efficacy of PNU-142633, a selective 5-HT(1D) agonist, in patients with acute migraine. Cephalalgia 2001;21:727-732.
21. Gras J, Bou J, Llenas J, Fernandez AG, Palacios JM. Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol 2000;410:43-51.
22. Gras J, Cardelus I, Llenas J, Palacios JM. Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine. Eur J Pharmacol 2000;410:53-59.
23. Gras J, Llenas J, Palacios JM. Ebastine is without effect in a sensitive experimental model for detecting prolongation of the QTc interval. Allergy 1996;31:188 (Abstr.).
24. Gras J, Llupià J, Llenas J, Palacios JM. Safety profile of almotriptan, a new antimigraine agent. Effects on central nervous system, renal function and respiratory dynamics. Arzneimittelforschung 2001;51:726-732.
25. Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, Tucker ML. Preclinical studies on the anti migraine drug, sumatriptan. Eur Neurol 1991;31:282-290.
26. 1-like receptor agonist, GR43175. Cephalalgia 1989;9(Suppl 9):23-33.
27. Johnston BM, Saxena PR. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol 1978;63:541-549.
28. Lloyd K. The clinical profile of sumatriptan: sa fety and tolerability. Eur J Neurol 1994;34(Suppl 2):40-43.
29. Martinez E, Cabarrocas X, Peris F, Ferrer P, Luria X. Meta-analysis of the efficacy and safety of almotriptan in the treatment of migraine. Cephalalgia 1999;19:362 (Abstr.).
30. May A, Gijsman HJ, Wallnofer A, Jones R, Diener HC, Ferrari MD. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996;67:375-378.
31. 1B receptors in human cerebral arteries: Pharmacological characterization and localization with immunochemistry. Br J Pharmacol 1999;128:1133-1140.
32. Owen K, Hartley K, Tucker ML, Parkinson MM, Tweats DJ, Jackson MR. The preclinical toxicological evaluation of sumatriptan. Hum Exp Toxicol 1995;14:959-973.
33. 1-like receptors. Naunyn-Schmiedeberg's Arch Pharmacol 1992;346:592.
34. Pascual J. Therapy with other triptans: Almotriptan. In: Diener HC, ed. Monographs in Clinical Neurosciences. Volume 17. Drug treatment of migraine and other frequent headaches. Basel: Karger, 2000;197-205.
35. 1B/D agonist for the symptomatic treatment of migraine. Exp Rev Neurother 2001;1:20-27.
36. Pascual J, Cabarrocas X. Within-patient early vs delayed treatment of migraine attacks with almotriptan: The sooner the better. Headache 2002;42:28-31.
37. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000;20:588-596.
38. Pascual J, Peris F, Cabarrocas X, Luria X. Meta-analysis of the efficacy of almotriptan in the treatment of acute migraine attacks. Cephalalgia 2001;21:427 (Abstr.).
39. Robert M, Warrington S, Zayas JM, Cabarrocas X, Ferrer P. Cardiovascular safety of almotriptan in healthy volunteers. 41st Meeting of the Association for the Study of Headache, Boston, 11-13 June, 1999.
40. Salvà M, Palacios JM, Martinez-Tobed A. Metabolism of the novel anti-migraine compound almotriptan (LAS 31416) in humans. 6th ISSX meeting, 30 June to 3 July, 1997:174 (Abstr).
41. 1D receptor agonists. Exp Opin Invest Drugs 1996;5:581-593.
42. Saxena PR, Vlaam-Schluter GM. Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine-studies in an experimental model for migraine. Headache 1974;13:44-54.
43. Schoenen J. Acute migraine therapy: The newer drugs. Curr Opin Neurol 1997;10:237-243
44. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259-1287.
45. 1 receptors in the vertebrate brain: regional distribution examined by autoradiography. Naunyn-Schmiedeberg's Arch Pharmacol 1989;34:486.